XML 61 R54.htm IDEA: XBRL DOCUMENT v3.25.2
License and Collaboration Agreements - Additional Information (Detail)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Nov. 30, 2020
USD ($)
Jan. 31, 2024
USD ($)
Oct. 31, 2023
USD ($)
Apr. 30, 2023
USD ($)
Jan. 31, 2023
USD ($)
Jun. 30, 2022
USD ($)
Apr. 30, 2022
USD ($)
Aug. 31, 2021
USD ($)
Jun. 30, 2025
USD ($)
License
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
License
Jun. 30, 2024
USD ($)
Dec. 31, 2023
USD ($)
Jan. 31, 2021
USD ($)
Oct. 31, 2020
USD ($)
SYFOVRE [Member]                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Regulatory milestone payments   $ 3,000,000 $ 2,000,000 $ 2,300,000                      
Royalty expense                 $ 4,900,000 $ 5,000,000 $ 9,200,000 $ 9,500,000      
Regulatory milestone incurred                         $ 5,000,000    
EMPAVELI and Aspaveli [Member]                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Milestone payments based on annual sales milestones   1,500,000                          
Royalty expense                 1,700,000 1,600,000 3,300,000 3,100,000      
Swedish Orphan Biovitrum AB (Publ) [Member] | Aspaveli [Member]                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Royalty Revenue                 5,900,000 4,400,000 12,000,000 8,900,000      
Collaboration and License Agreement [Member] | Swedish Orphan Biovitrum AB (Publ) [Member]                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Upfront payment $ 250,000,000                            
Milestone payment received for achievement of regulatory development milestone             $ 50,000,000                
Development cost reimbursement received                     65,000,000        
Waived Payment                     $ 15,000,000        
Royalties entitled to receive after first commercial sale of applicable licensed product period                     10 years        
Contract research and development expense                 0 0 $ 0 0      
Revenue recognized                 1,200,000 $ 16,100,000 12,000,000 $ 20,900,000      
Collaboration and License Agreement [Member] | Swedish Orphan Biovitrum AB (Publ) [Member] | Maximum [Member]                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Aggregate milestone payments upon achievement of specified one time regulatory development and commercial milestone events                             $ 915,000,000
Development cost reimbursement                     80,000,000        
University of Pennsylvania [Member]                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Development milestone achievement               $ 1,000,000              
Additional payment upon for sublicense fee related to collaboration agreement           $ 5,000,000                  
University of Pennsylvania [Member] | EMPAVELI and Aspaveli [Member]                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Milestone payments based on annual sales milestones         $ 1,000,000                    
University of Pennsylvania [Member] | Maximum [Member]                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Aggregate milestones payments                 $ 3,200,000   3,200,000        
Milestone payments based on annual sales milestones                     $ 5,000,000        
2010 License Agreement [Member]                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Number of licensed products | License                 2   2        
2010 License Agreement [Member] | Maximum [Member]                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Aggregate milestones payments                 $ 1,700,000   $ 1,700,000        
Milestone payments based on annual sales milestones                     $ 2,500,000        
Sobi Agreement and Another Licensing Transaction [Member]                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Sublicense fee owed   $ 500,000                       $ 25,000,000